Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06603597 · ClinicalTrials.gov registry record
HER2-positive Breast Cancer Registry
A clinical trial of HER2 + Breast Cancer, sponsored by Priyanka Sharma.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 6
- Study locations
NCT06603597 is a study of HER2 + Breast Cancer that is actively recruiting participants, run by Priyanka Sharma. The registered enrollment target is 1,000 participants, above the 196-participant average among 8 other HER2 + Breast Cancer trials with a reported enrollment target (410% higher). The trial reports 6 study locations across 2 states.
The verdict
NCT06603597, a study of HER2 + Breast Cancer, is actively recruiting participants, sponsored by Priyanka Sharma.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this observational study is to better understand links between patient or tumor characteristics and outcomes in HER2-positive breast cancer.
Conditions Studied
Study Locations (6)
Kansas
- KUCC - Indian Creek - Overland Park
- KUCC - Overland Park - Overland Park
- KUCC - Briarcliff - Westwood
- KUCC - Olathe - Westwood
- The University of Kansas Cancer Center - Westwood
Missouri
- KUCC - Lee's Summit - Lee's Summit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2024-09-27 |
| Est. Completion | 2044-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06603597
The ClinicalTrials.gov registry entry for NCT06603597 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 196-participant average among 8 other HER2 + Breast Cancer trials with a reported enrollment target (410% higher). The listed sponsor is Priyanka Sharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HER2 + Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06603597 reports 6 study locations spanning 2 distinct geographic areas - top geographies include Kansas, Missouri.
Frequently Asked Questions
What is clinical trial NCT06603597 about?
NCT06603597 is a clinical study titled "HER2-positive Breast Cancer Registry". The goal of this observational study is to better understand links between patient or tumor characteristics and outcomes in HER2-positive breast cancer.
What is the current status of trial NCT06603597?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2024-09-27. Estimated completion is 2044-10.
What conditions does trial NCT06603597 study?
This clinical trial studies the following conditions: HER2 + Breast Cancer.
Who is sponsoring clinical trial NCT06603597?
This trial is sponsored by Priyanka Sharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06603597 being conducted?
This trial has 6 study locations across Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2 + Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RECRUITING · Phase 1
-
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
RECRUITING · Phase 1
-
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
RECRUITING
-
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
RECRUITING · Phase 2
-
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
RECRUITING · Phase 2
-
Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment (HER2 CR)
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.